Inclusion Criteria:

1. Cytologic or histologic proof of adenocarcinoma of the pancreas is required prior to
treatment. Patients can have tumor originating in any part of the pancreas. Islet
cell tumors are not eligible. Only patients with non- metastatic, unresectable
disease (AJCC 2002 stage T4 NX M0) are eligible. Computed Tomography (CT) findings of
lung, liver, peritoneal metastasis are equivocal, are eligible. Patients who cannot
undergo resection because of underlying medical problems are also eligible. Diagnosis
of Pancreatic Adenocarcinoma by bile duce brushings are acceptable. Patients with
regional nodal disease are eligible.

2. All patients must be staged with a physical exam, chest X-ray (CXR), and
contrast-enhanced helical thin-cut abdominal CT. Unresectability is defined by CT
criteria: a) evidence of tumor extension to the celiac axis or superior mesenteric
(SM) artery, or b) evidence on either CT or angiogram of occlusion of the SM vein or
SM/ portal vein confluence. If a tumor does not meet this definition and is found to
be unresectable at surgical exploration, then that tumor is considered unresectable.

3. Patients must be 18 years and older. There will be no upper age restriction

4. Karnofsky performance status greater than or equal to 70 are eligible.

5. Patients must either be not of child bearing potential or have a negative urine
pregnancy test within 72 hours of treatment. Patients are considered not of child
bearing potential if they are surgically sterile (they have undergone a hysterectomy,
bilateral tubal ligation or bilateral oophorectomy) or they have been postmenopausal
for at least 12 months.

6. Women of childbearing potential must agree to practice adequate contraception and to
refrain from breast-feeding, as specified in the informed consent. Sexually active
males must practice contraception during the study.

7. Bone marrow function: absolute neutrophil count (ANC) >1,500/ul. Platelets
>100,000/ul.

8. Renal function: creatinine clearance >30 mL/min (calculated with Cockcroft-Gault
equation).

9. Hepatic function: Total bilirubin less than 5mg/dL. If the patient required an
endobiliary stent, the bilirubin level must have declined on consecutive measurements
indicating adequate biliary decompression; alanine aminotransferase (ALT) less than
or equal to 5 times the upper limit of normal.

10. Neurologic function: neuropathy (sensory) < Common Toxicity Criteria (CTC) Grade 2.

11. Patients must sign a study-specific consent form, which is attached to this protocol.

Exclusion Criteria:

1. Patients with a history of prior metastatic cancer.

2. Patients must not have significant infection,i.e., requiring intravenous (IV)
antibiotics, or other coexistent medical condition that would preclude protocol
therapy.

3. Significant history of uncontrolled cardiac disease; i.e., uncontrolled hypertension,
unstable angina, recent myocardial infarction (within prior 6 months), uncontrolled
congestive heart failure, and cardiomyopathy with ejection fraction less than <30%.

4. Prior therapy which specifically and directly targets the estimated EGFR pathway.

5. Prior severe infusion reaction (bronchospasm, stridor, urticaria and/or hypotension)
to a monoclonal antibody.

6. Any prior history of radiotherapy to the abdomen.

7. History or evidence upon physical examination of central nervous system (CNS) disease
(e.g., primary brain tumor, seizures not controlled with standard medical therapy,
any brain metastases, or history of stroke)

8. Prior unanticipated severe reaction to fluoropyrimidine therapy or known
hypersensitivity to 5-fluorouracil.

9. Patients who have had an organ allograft.

10. Patients on Coumadin must be changed to Lovenox at least 1 week prior to starting
capecitabine. Low dose (1 mg) Coumadin is allowed.

11. Patients taking Sorivudine or Brivudine A must be off of these drugs for 4 weeks
prior to starting capecitabine. Patients taking cimetidine must have this drug
discontinued. Ranitidine or a drug from another anti-ulcer class can be substituted
for cimetidine if necessary.